UK medicines regulator says information on boxes of montelukast will alert users to risk of mood and behaviour changes
More than 500 adverse neuropsychiatric reactions have been reported in children under the age of nine involving an asthma drug which is to get new warnings over its risks.
The Medicines and Healthcare products Regulatory Agency (MHRA) announced last week that more prominent warnings would be added to the information provided on boxes of the asthma drug montelukast, sold under the brand name Singulair.
About Author
More Stories
Virologist Wendy Barclay: ‘Wild avian viruses are mixing up their genetics all the time. It’s like viral sex on steroids’
Microsoft unveils chip it says could bring quantum computing within years
Trump administration retreats in fight against Russian cyber threats